A.M. vitals: Novartis to two drugs, scrap-take charge $ 590 million
End of the Line: Novartis takes scrapping a 590 million US dollars to cover the costs of work on two experimental drugs — one an antifungal agent that chronic hepatitis C, the other the WSJ
No comments:
Post a Comment